Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Advanced Glycation End Products Market, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,368.5 million in 2020 and is expected to exhibit a CAGR of 6.3% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing prevalence of diabetes is expected to boost the market growth over the forecast period. For instance, according to the study titled 'Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition', published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people were estimated to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.

Global Advanced Glycation End Products Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic is expected to hamper the global advanced glycation end products market growth during the forecast period. The COVID-19 pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare sector has been impacted majorly due to the COVID-19 pandemic. Many clinical trials have been suspended during the pandemic. In order to restart the clinical trials, the U.S. Food and Drug Administration (FDA) released guidelines during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency. The appendix of the guidelines also provide answers to some general questions, which the U.S. Food and Drug Administration (FDA) received from various sponsors and researchers about conducting clinical trials during the COVID-19 public health emergency.

Furthermore, players operating in the global advanced glycation end products market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing drug formulations due to irregularities in transportation facility. Moreover, distributors of products are experiencing irregular demand for products from the retailers due to increasing patient population suffering from COVID-19 and other life threatening disorders.

The global advanced glycation end products market is estimated to be valued at US$ 1,368.5 million in 2020 and is expected to exhibit a CAGR of 6.3% during the forecast period (2020-2027). 

Browse 25 Market Data Tables and 20 Figures spread through 105 Pages and in-depth TOC on “Advanced Glycation End Products Market”- Global Forecast to 2027, by Type (Non-fluorescent AGEs (Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline) and Fluorescent AGEs (Pentosidine and Methylglyoxal-lysine dimer (MOLD))), by Application (Diabetic Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others), by End User (Hospitals, Specialty Clinics, and Homecare Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global advanced glycation end products market, click the link below:

https://www.coherentmarketinsights.com/market-insight/advanced-glycation-end-products-market-4350

Increasing prevalence of cancer is propelling growth of the global advanced glycation end products market. For instance, according to the World Health Organization (WOH) estimates published in 2018, 18.1 million new cancer cases are reported every year across the globe. Among these, 300,000 cases are diagnosed among children aged 0 to 19 years.

Key Takeaways of the Global Advanced Glycation End Products Market:

  • The global advanced glycation end products market is expected to exhibit a CAGR of 6.3% over the forecast period, owing to increasing number of cardiovascular diseases. For instance, according to the Global Burden of Disease (GBD), an article published in the National Center for Biotechnology Information (NCBI) in July 2020, prevalence of ischemic heart disease was found to be increasing. The GBD datasets analyzed that in 2020, the prevalence rate of ischemic heart disease was 1,655 per 100,000 population, and is expected to exceed 1,845 by 2030.
  • Among type, non-fluorescent AGEs products segment accounted for largest market share in 2019, owing to extensively studied and implicated for treatment of in diabetes, inflammation, and other diseases.
  • Among application, cancer segment accounted for largest market share in 2019, owing to increasing cases of cancer globally. For instances, according to the World Cancer Research Fund International, worldwide total number of new cancer cases diagnosed in 2018 were 17,036,901.
  • Key players operating in the global advanced glycation end products market include Merck KGaA, Diagnoptics Technologies B.V., Cell Biolabs, Inc., Shanghai Korain Biotech Co., Ltd, Scent-Sations, Inc., Z.I. de la Nau, and KOKEN CO., LTD. among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner